Given the lack of consensus on specific cutoff values for AD biomarkers, we excluded subjects with tau biomarker levels in the highest quartile and follow-up times in the lowest quartile (i.e., ≤ 3 years). The gene discussed is MAPT; the disease is Alzheimer disease.